Osrodek Badawczo Naukowo Dydaktyczny Chorob Otepiennych Im. Ksiedza Henryka Kardynala Gulbinowicza Osrodek Alzheimerowski Sp. z o.o. — Clinical Trial Site

9 Registered trials

2 Currently recruiting

Organisation

Osrodek Badawczo Naukowo Dydaktyczny Chorob Otepiennych Im. Ksiedza Henryka Kardynala Gulbinowicza Osrodek Alzheimerowski Sp. z o.o.

Location

Scinawa, Poland

Identifier

ORG-100044295

Address

Ul. Jana Pawla II Nr 12, 59-330, Poland

Departments

#40638:Osrodek Badawczo-Naukowo-Dydaktyczny Chorob Otepiennych Im.
n/a
NA
Ośrodek Alzheimerowski w Ścinawie

Clinical trials at this site (9)

Search interface

A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-12
A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w… Recruiting

2023-504151-27-00 Psychosis associated with Alzheimer’s Disease 5 2024-05-09
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26
A study to see how well KarXT works and how well tolerated it is in participants with psychosis associated with Alzheimer’s disease. Ended

2023-504416-16-00 Psychosis Associated with Alzheimer’s Disease 5 2024-04-11
A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended

2023-506170-12-00 Alzheimer’s Disease 4 2021-10-18
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended

2023-506918-45-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended

2023-506919-18-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended

2023-504990-19-00 Agitation in Patients With Dementia of the Alzheimer's 5 2021-04-06
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended

2023-507303-55-00 Alzheimer Disease 4 2020-09-30